Knowledge of whether a tumor is unicellular or multicellular in origin may provide important insight into its pathogenesis. Information relevant to this point can be obtained by studying neoplasms arising in individuals with two or more genetically different cell populations, such as females heterozygous for the X-linked glucose-6-phosphate dehydrogenase (G-6-PD) locus. In these subjects, a given cell or clone of cells shows only one of the two enzyme types seen in a mixture of their cells." 2 For example, electrophoretic analyses of mass cultures of fibroblasts derived from females heterozygous for the A and B genes at the G-6-PD locus show both type A and type B enzyme, whereas analyses of clones originating from single cells derived from the mass cultures show either type A or type B enzyme but never both A and B.2 Thus, neoplasms arising from a single cell in heterozygous females should exhibit only one enzyme type, while those with a multicellular origin should contain both enzymes.
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In the first application of this system to the study of neoplasms, Linder an 86-year-old woman who was being treated with busulfan. At the time of study the peripheral white blood count was 18,000 cells per mm3 of which 3% were metamyelocytes, 7% band forms, 69% mature polymorphonuclear cells, and 21% were mononuclear cells. Case 3 was a 22-year-old woman who had been treated with busulfan for two months. Two weeks before the time of study the peripheral white blood count was 31,500 cells per mm3 of which 3% were myeloblasts, 35% myelocytes, 13% metamyelocytes, 23% neutrophils, 5% basophils, 5% eosinophils, and 16% were mononuclear cells.
Methods. Blood was drawn in heparin for preparation of granulocytes7 and in acid-citrate-dextrose for preparation of hemolysates of red blood cells (RBC's). Attempts at preparing lymphocytes were unsuccessful due to the relative paucity of those cells. Cells of the granulocytic series comprised 90 and 91 per cent of the total cells in the white cell preparations used for enzyme analysis in Cases 1 and 2, respectively. In the third case cellular morphology was not sufficiently preserved to allow accurate counts. The granulocytes were disrupted by ultrasound and extracts were prepared. Small skin biopsies were obtained from the patients for tissue culture.8 After the third transfer, the fibroblasts derived from the skin biopsies were harvested, washed in saline, resuspended in 1 ml of 1 X 10-4 M NTADP in distilled water, and exposed to repeated freezing and thawing. Aliquots of the erythrocyte, granulocyte, and fibroblast preparations were subjected to starch gel electrophoresis9 and in Case 1 also to CM-Sephadex column chromatography.10
Results.
-After starch gel electrophoresis, both A and B type enzymes were found in preparations of fibroblasts from the cell cultures of each of the three patients (see Fig. 1 ), indicating that the patients were heterozygous at the G-6-PD locus.
In contrast, only one enzyme type (type A) was demonstrable in erythrocyte and granulocyte preparations from the three patients. Since the high peripheral white blood count in Case 1 made it likely that freshly prepared RBC hemolysates were significantly contaminated by granulocytes, hemolysates were also prepared from washed erythrocytes that had been stored imthe-rfigerorin acid-citrate-dextrose for six weeks. Under these circumstances the great majority of granulocytes had undergone lysis and the washed RBC's were relatively pure. Again, only type A enzyme was demonstrable in these cells.
Column chromatography'0 was done with material from Case 1 and, as with starch gel electrophoresis, two enzyme types were found in skin cells, but only one enzyme type was found in erythrocytes and granulocytes.
Discussion.-The presence of a single G-6-PD type in the blood cells of our three patients who are heterozygous for the G-6-PD locus is compatible with the suggestions of a clonal origin of the tumor and of a common stem cell for red blood cells and granulocytes. However, several alternative explanations for these findings should be mentioned. For example, it is conceivable that the leukemic process alters type B G-6-PD so that it cannot be distinguished from type A enzyme by our methods. In order to explore this possibility two patients with CML and type B enzyme in their fibroblasts were studied. In both cases typical type B enzyme was demonstrable in erythrocyte and granulocyte preparations.
Another possible explanation for the presence of only one enzyme type in the RBC's and granulocytes of our patients with CML who are heterozygous for the G-6-PD locus is that during the process of random X-chromosome inactivation in embryogenesis the same X chromosome in every hematopoietic precursor cell was inactivated. Occasionally only one type of G-6-PD is seen in RBC's from normal individuals who are genetically known to be heterozygous for the G-6-PD locus. The available data suggest that this event is unusual and probably occurs with a frequency less than 0.05. Thus, the chance that the RBC's in our three patients had only one type of G-6-PD before they contracted CML (and, therefore, independently of CML) is very small.
Still another possibility is that malignant transformation occurs in several or many cells and the cells producing type A enzyme then selectively overgrow those producing B enzyme. Since A and B cells coexist indefinitely in the great majority of heterozygotes, there seems to be no a priori reason for assuming that a malignantly transformed A cell will outgrow a similarly transformed B cell. Thus, it is more probable that the finding of only one type of G-6-PD in preparations derived from millions of granulocytes from patients with chronic myelocytic leukemia who are heterozygous for the G-6-PD locus indicates a clonal origin of CML. It seems likely that the leukemia arises as a result of a rare event (e.g., somatic mutation) in a single cell.
Studies Summary.-The G-6-PD types of erythrocytes, granulocytes, and skin cells in three patients with CML were determined. The patients were heterozygous at the G-6-PD locus, so that two enzyme types were found in skin cells. The fact that only one type was found in erythrocytes and granulocytes was interpreted as strong evidence that erythrocytes and granulocytes have a common stem cell and that CML has a clonal origin. It appears most likely that this malignancy arises as a consequence of a rare event in a single stem cell.
